drugset / Trial / NCT04655716

Urine Alkalinisation to Prevent AKI in COVID-19

NCT04655716

Phase 3 Unknown 80 enrolled Guy's and St Thomas' NHS Foundation Trust
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim is to explore the feasibility and safety of urine alkalinisation in critically ill patients with COVID-19.

Timeline

Start
2021-07-19
Primary completion
2022-06-30
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject sodium bicarbonate Diagnostic / imaging agent 150 meq Intravenous

Indications